|
NIAID's divisions are particularly interested in applications that address the areas listed below. Also read NIAID's section of the Small Business Program Descriptions and Research Topics.
Division of AIDS -- Small Business High-Priority Areas of Interest
Updated April 29, 2008.
| Areas of Interest |
Contact |
Email |
Phone |
| Preclinical development and evaluation of HIV vaccines, adjuvants, delivery systems, and novel technologies to enhance vaccine potency to prevent HIV infection or disease. |
Yen Li |
yli@niaid.nih.gov |
301-496-3816 |
| Development of anti-HIV agents directed at new viral or cellular targets. |
Paul Black |
pblack@niaid.nih.gov |
301-496-2970 |
| Development of novel anti-HIV drugs and therapeutics with focus on technological aspects such as multiplex analysis of drugs and better means of drug screening and drug delivery. |
Kailash Gupta |
kgupta@niaid.nih.gov |
301-435-3724 |
| Preclinical microbicide development of combination
microbicides (multiple compounds, targets of activity against HIV and STIs associated with HIV acquisition); new chemical classes with specific mechanisms of action and antiviral targets, new microbicide targets, and formulation
and delivery approaches for new and existing microbicides. |
Jim A. Turpin |
jturpin@niaid.nih.gov |
301-451-2732 |
| Development, standardization, validation, and evaluation of improved technologies to detect HIV, to evaluate immune responses to HIV vaccines, or to correlate immune responses associated with vaccine efficacy. |
Marco Schito |
schitom@niaid.nih.gov |
301-594-5374 |
| Development and evaluation of practical and affordable tests to measure viral load, CD4+ cell counts, and drug toxicities to monitor populations in resource-poor settings. Development of tests to detect early infection in seropositive HIV-infected individuals. |
Michael Ussery |
mussery@niaid.nih.gov |
301-402-0134 |
| Development of new therapeutic options for treatment of MDR-TB and XDR-TB in the setting of HIV infection and antiretroviral therapy. Development of rapid diagnostic tests for tuberculosis/HIV, TB drug resistance, and monitoring response to therapy. |
Chris Lambros |
cl29r@nih.gov |
301-435-3769 |
| Preclinical discovery and development of antimicrobial agents directed against Mycobacterium avium, Pneumocystis pneumonia, and Cryptococcus neoformans (and other pathogenic fungi). |
Chris Lambros |
cl29r@nih.gov |
301-435-3769 |
| Preclinical development and evaluation of therapeutic vaccines and other immune-based therapies to attenuate HIV disease progression or reduce HIV infectiousness. |
Tony Conley |
conleyto@niaid.nih.gov |
301-451-2739 |
| Development of gene therapies for HIV. |
Frosso Voulgaropoulou |
frossov@mail.nih.gov |
301-451-2704 |
| Research to assess and overcome specific biomedical obstacles in HIV vaccine discovery, especially by application of novel technology to vaccine discovery or by the development and supply of novel reagents and other resources useful in novel vaccine discovery. |
Stuart Shapiro |
sshapiro@niaid.nih.gov |
301-402-0122 |
| Preclinical pre-exposure prophylaxis (PrEP) development (single or multiple agents, immunological, pharmacological, or other potential approaches directed against viral and/or host targets), including new classes of agents, examination of specific mechanisms of action and antiviral targets, new formulation procedures and delivery strategies for PrEP agents, optimization of animal models, and related research. |
David Burns |
burnsda@niaid.nih.gov |
301-435-8896 |
Division of Allergy, Immunology, and Transplantation -- Small Business High-Priority Areas of Interest
Updated December 24, 2008.
| Areas of Interest |
Contact |
Email |
Phone |
| Development of medical countermeasures to protect against, mitigate, and treat the short- and long-term effects of radiation exposure due to terrorist attack. |
Andrea DiCarlo-Cohen |
ad292x@nih.gov |
301-451-9199 |
| Development of novel or improved decorporation agents to remove radionuclides from the body following accidental inhalation, ingestion or wound entry. |
David Cassatt |
dc458x@nih.gov |
301-451-3124 |
| Identification of radiation exposure biomarkers and development of new biodosimetry methods and devices for triage of radiation-exposed people. |
Narayani Ramakrishnan |
nr57h@nih.gov |
301-451-3101 |
| Novel approaches for detecting infants at
risk for developing asthma and other allergic diseases. |
Matthew Fenton |
fentonm@niaid.nih.gov |
301-496-8973 |
| Immune targets for asthma and allergic disease
interventions. Development of immunotherapies to prevent or treat allergic diseases. |
Matthew Fenton |
fentonm@niaid.nih.gov |
301-496-8973 |
| Single cell assays to isolate and study allergen-specific lymphocytes. |
Matthew Fenton |
fentonm@niaid.nih.gov |
301-496-8973 |
| Development of new reagents and non-muting animal models for allergy research. |
Matthew Fenton |
fentonm@niaid.nih.gov |
301-496-8973 |
| Innovative treatments for autoimmune diseases. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| Biomarkers to measure risk, disease activity,
and therapeutic response in autoimmune diseases. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| High throughput assay of T-cell activity
in autoimmune diseases. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| Standardized validated diagnostic criteria
and outcome measures for autoimmune diseases correlated with disease
activity. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| Innovative treatments for primary immunodeficiencies. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| Diagnostic tests to identify or screen for primary immunodeficiencies. |
Josiah Wedgwood |
jw472t@nih.gov |
301-496-7104 |
| Immunotherapeutic antibodies and agents against
bioterriorism pathogens
(Category A-C). |
Helen Quill |
hq1t@nih.gov |
301-496-7551 |
| Biomarkers of host immune defense to bioterriorism
pathogens (Category A-C). |
Helen Quill |
hq1t@nih.gov |
301-496-7551 |
| Single cell assay for study of human
immunology. |
Helen Quill |
hq1t@nih.gov |
301-496-7551 |
| Methods and analysis tools to facilitate high throughput, high resolution MHC typing in humans and non-human primates. |
Kristy Kraemer |
kkraemer@niaid.nih.gov |
301-496-5598 |
| Immunomodulatory agents to prevent graft rejection and biomarkers to predict transplantation outcomes. |
Nancy Bridges |
nbridges@niaid.nih.gov |
301-496-5598 |
Source animals, reagents, and diagnostic tools for xenotransplantation |
Crystal Koh |
ckoh@niaid.nih.gov |
301-496-5598 |
Division of Microbiology and Infectious Diseases -- Small Business High-Priority Areas of Interest
Updated December 26, 2007.
| Areas of Interest |
Contact |
Email |
Phone |
Vaccines for NIAID Category A, B, and C priority pathogens including influenza, Ebola, Marburg, arenavirus, and other viral encephalitides. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Vaccine development for tuberculosis, STIs, hepatitis B and C, and malaria and other high-impact global parasitic diseases. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Vaccine enhancement and formulation technologies with the goal of providing protection against multiple infectious disease agents, providing accelerated immune responses (more rapid schedules or reduced number of immunizations), increase ease of administration (i.e., self-administration), and increase product stability to minimize cold chain requirements. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Therapeutics for NIAID Category A, B, and C priority pathogens including smallpox, viral hemorrhagic fevers, viral encephalitides, botulinum neurotoxins, and influenza. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Therapeutics for tuberculosis, hepatitis B and C, and malaria and other high-impact global parasitic diseases. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Therapeutics exhibiting broad-spectrum activity against microbial pathogens. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Therapeutic enhancement and formulation technologies with the goal of improving drug development timeframes, productivity, efficacy, specificity, safety, stability, and delivery. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Diagnostics for point-of-care applications for NIAID Category A, B, and C priority pathogens including influenza and those causing emerging and re-emerging infectious diseases. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
Diagnostics for tuberculosis, STIs, community acquired pneumonia, and malaria and other high impact, global parasitic diseases. |
Barbara Mulach |
bm244j@nih.gov |
301-496-1884 |
|
